An Open-label, Non-controlled, Multicentre, Pilot Clinical Trial of Inhaled Molgramostim in Subjects With Antibiotic-resistant Non-tuberculosis Mycobacterial (NTM) Infection
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Molgramostim (Primary)
- Indications Bacterial infections; Mycobacterial infections
- Focus Therapeutic Use
- Acronyms OPTIMA
- Sponsors Savara Pharmaceuticals
- 03 Apr 2018 Status changed from not yet recruiting to recruiting.
- 29 Jan 2018 Status changed from planning to not yet recruiting.
- 16 Nov 2017 According to a Savara media release, this Phase IIa study is expected to be initiated in early 2018.